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ABSTRACT
Purpose Following two cases of neutralizing antibodies to
epoetin alfa in an investigational clinical study, a small number of
individual syringes of two drug product batches were found to
contain unusually high levels of aggregation at the end of the
clinical trial.
Methods We undertook an extensive analytical approach to
determine the root-cause of the increased aggregation in the
affected batches.
Results Soluble tungsten was found in the syringes, most likely
derived from the pins used to manufacture the syringes. Spiking
of epoetin alfa with sodium polytungstate or an extract of
tungsten pins used to manufacture the syringes induced the
formation of aggregates, both dimers that appeared to be
covalently linked by disulphide bonds as well as higher-order
aggregates. Sodium polytungstate had also a strong denaturing
effect on the protein.
Conclusions We propose tungsten-mediated unfolding and
aggregation of epoetin alfa in pre-filled syringes as a potential
root cause for increased immunogenicity. This finding may be
more broadly applicable to this and other classes of therapeutic
proteins.
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ABBREVIATIONS
AF4 asymmetric-flow field-flow fractionation
CD circular dichroism
CKD chronic kidney disease
C4-RP-HPLC reversed-phase chromatography
KD equilibrium binding constant
HP-SEC high-performance size exclusion
chromatography
HSA human serum albumin
ICP-OES inductively coupled plasma-optical
emission spectrometry
ITC isothermal titration calorimetry
LO light obscuration
MFI micro-flow imaging
PRCA pure red cell aplasia
RU resonance units
SDS-PAGE sodium dodecyl sulphate-polyacrylamide
gel electrophoresis
SPR surface plasmon resonance
TFA trifluoroacetic acid
A. Seidl (*):O. Hainzl:M. Richter:R. Fischer:M. Hartinger
Sandoz Biopharmaceuticals, Hexal AG
Keltenring 1 + 3
82041 Oberhaching, Germany
e-mail: andreas.seidl@sandoz.com
S. Böhm: B. Deutel: J. Windisch
Sandoz Biopharmaceuticals, Sandoz GmbH
Kundl, Austria
N. Casadevall
Hôpital Saint Antoine
Paris, France
G. M. London
Manhes Hospital
Fleury-Mérogis, France
I. Macdougall
King’s College Hospital
London, UK
Pharm Res (2012) 29:1454–1467
DOI 10.1007/s11095-011-0621-4INTRODUCTION
Recombinant human erythropoietins have revolutionized
the treatment of anemia associated with chronic kidney
disease (CKD), and have been used for more than two
decades. Pure red cell aplasia (PRCA) is a rare adverse
effect of treatment with epoetins resulting from antibodies
to the therapeutic product that cross-react with endogenous
erythropoietin. PRCA is characterized by a rapidly pro-
gressive, severe anemia and by a complete absence of
erythroid precursor cells in the bone marrow (1).
Before 1998, there were only three fully documented
reports of anti-drug antibody-mediated PRCA following
administration of epoetins (2). This situation changed in
1998, when manufacturing modifications, including the
replacement of human serum albumin (HSA) as a stabilizer
by the synthetic detergent polysorbate 80 and glycine, were
introduced to epoetin alfa marketed outside the USA
(Eprex
®/Erypo
®; hereafter referred to as Eprex
®). Follow-
ing this formulation change, the incidence of epoetin-
associated PRCA increased dramatically (2,3). By Septem-
ber 2002, the number of PRCA cases with documented
neutralizing antibodies had risen to 112. In December
2002, the marketing authorization for subcutaneous ad-
ministration of Eprex
® was withdrawn. Root-cause inves-
tigations by the manufacturer of Eprex
® led to the proposal
that polysorbate 80 caused enhanced leaching of organic
compounds from uncoated rubber stoppers in the drug
syringes; it was hypothesized that these compounds acted as
adjuvants, leading to the formation of neutralizing anti-
bodies and the development of PRCA (4,5). However, it is
unclear whether an adjuvant alone can provoke breakdown
of B-cell tolerance and induce the formation of antibodies
against a self-protein, or if additional factors are involved
(6–8).
More recently, two cases of neutralizing antibodies were
reported during a pre-marketing clinical trial of a biosimilar
epoetin (HX575) in subcutaneous administration in chronic
renal failure subjects (9). In this paper, we present data
showing that contamination by tungsten during the man-
ufacture of the syringes used for primary packaging is the
most likely cause of protein denaturation and aggregation,
which may have led to the occurrence of two cases of
neutralizing antibodies in the investigational clinical trial.
MATERIALS AND METHODS
Size-Exclusion Chromatography (HP-SEC)
Separation of epoetin monomer, dimer and higher-order
aggregates under native conditions was performed on a
BioSep
® SEC S3000 column (30×0.78 cm, 5 μm) using an
isocratic mobile phase containing 0.4 M NaCl, 8.1 mM
Na2HPO4/1.5 mM KH2PO4 at pH 7.4, with a flow rate of
0.4 ml/min. For detection, a diode array detector was used
with a detection wavelength of 206 nm (bandwith 2 nm),
and a reference wavelength of 245 nm (bandwith 2 nm) to
suppress the signal from polysorbate 80.
Reversed-Phase Chromatography (C4-RP-HPLC)
Separation of the epoetin monomer and irreversible dimer
was performed on a reversed-phase C4 column (15×0.21 cm,
5 μm, 300A) from Vydac using a gradient mobile phase of
0.08% trifluoroacetic acid (TFA) in water (mobile phase A)
and 0.06% TFA in acetonitrile (mobile phase B). The column
was initially equilibrated with 5% B at a flow rate of 0.3 ml/
min. The separation was performed using a linear gradient of
5 %Bt o3 8 %Bf o r5m i n ,3 8 %Bt o5 0 %Bf o r2 0m i na n d
50% B to 100% B for 5 min, followed by isocratic elution for
5minandflushingtothestartingconditions(5%B).Detection
was performed using a diode array detector with a detection
wavelength of 206 nm (2) and a reference wavelength of
250 nm (2). The column temperature was set to 30°C and an
injection volume of 100 μl was chosen for sample concen-
trations between 16.8 and 84.0 μg/ml.
Tungsten Determination
Protein solution (2.000 g) was mixed with 3.0 ml HNO3
(65%) and 3.0 ml deionised water. A microwave digestion
was performed (MLS mPrep A T640, T=210°C). The
solution was cooled to room temperature, transferred to a
PE-vial and filled to 20 ml with deionised water. Metals
were determined by inductively coupled plasma-optical
emission spectrometry (ICP-OES; Perkin Elmer OPTIMA
2000 DV). The limit of detection for chromium was
0.05 ppm, and for all other elements was 0.5 ppm.
Tungsten Spiking and Pin Extract Studies: Sample
Preparation
Tungsten spiking experiments were performed with six
tungsten species, all purchased from Sigma-Aldrich (Seelze,
Germany): tungsten metal powder (<10 μm), (Cat.
357421); tungsten (IV) oxide, (Cat 400505) and tungsten
(VI) oxide (Cat 204781) (poorly soluble); sodium tungstate
dihydrate (Cat 379751), ammonium tungstate (Cat 322385)
and sodium polytungstate (Cat 71913) (highly soluble).
A solution of 336 μg/ml of epoetin alfa in formulation
buffer (phosphate buffer, pH 7.0, containing the excipients
sodium chloride and polysorbate 80) was spiked with each
tungsten species to final tungsten concentrations of approx-
imately 2 ppm and 20 ppm. The amount of tungsten in
each sample was confirmed using ICP-OES.
Tungsten-Induced Aggregation of Epoetin 1455Tungsten pin extract was prepared from 100 used pins,
extracted for 2 h at room temperature in 20 ml epoetin alfa
f o r m u l a t i o nb u f f e rp l a c e di na nu l t r a s o n i cb a t h .T h e
solution was passed through a 0.2 μm filter to remove big
particles of tungsten oxides or tungsten metal. The tungsten
level in the extract was approximately 200 ppm. The pin
extract was added to a solution of 336 μg/ml of epoetin alfa
in formulation buffer to final tungsten concentrations of
approximately 2 and 20 ppm.
Samples were placed in clear type-I glass ampoules to
exclude syringe-related variables. Ampoules were filled with
700 μl of sample under inert gas (nitrogen), and stored at
2–8°C for 12 months or at 25°C for 6 months.
Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE)
SDS-PAGE was performed using NuPAGE
® Novex
® 4–
12% bis-Tris gels (1.00 mm×10 well) and the NuPAGE
®
MES SDS running buffer (Invitrogen). The SeeBlue
®
pre-stained protein standard was used as a molecular
weight marker. Samples were diluted with water to the
appropriate concentration, mixed 1:1 with sample buffer
and denatured for 5 min at 95°C. For reduced samples, 2-
mercaptoethanol was added to the sample buffer. The
denatured samples were centrifuged for 5 min and an
appropriate volume pipetted into the gel pockets. The
operating conditions were set according to the manufac-
turer’s instructions (22 V, 120 mA/gel at the start, 25 W:
run time 55 min). The gels were then stained with silver
(silver staining kit, SERVA) according to the manufac-
turer’s instructions.
Circular Dichroism (CD)
CD experiments were performed using a Chirascan plus
instrument (Applied Photophysics Ltd, Leatherhead, UK)
supplied with a thermostatted cell holder (QNW 250™,
Quantum Northwest Inc., Liberty Lake, WA, USA). Far-
UV CD experiments were run in quartz cuvettes of 0.5 mm
path length (Starna Optiglass Ltd, Hainault, UK) in the
wavelength range 195–250 nm, at a spectral resolution of
0.5 nm and a time constant of 0.2 s. CD experiments were
r u ni ne p o e t i na l f af o r m u l a t i o nb u f f e rw i t hv a r i a b l e
amounts of tungsten added. Time-resolved measurements
were performed at 208 nm, with 100 point measurements
at timed intervals of 40 s and a time constant of 1 s.
Surface Plasmon Resonance (SPR)
SPR experiments were performed on a Biacore T100
instrument (GE Healthcare, Biacore, Freiburg, Germany).
Epoetin alfa was coupled to the surface of a CM5 sensor
chip using a standard amine coupling procedure as
described by the manufacturer, yielding approximately
3,000 resonance units (RU). Measurements were performed
at 25°C in epoetin alfa formulation buffer at a flow rate of
10 μl/min. Increasing concentrations of sodium polytung-
state (0.67, 1.68, 3.35, 6.7, 10.1, 13.4, 16.8, 33.5 and
67 μM) were rinsed over the epoetin alfa-coupled chip
surface for 600 s. The apparent equilibrium constant (KD)
was calculated by plotting the steady-state binding signal
versus applied concentration of sodium polytungstate using a
least square algorithm based on the following equation:
RU ¼ RUmaxcCþ KD ðÞ
 1.
Isothermal Titration Calorimetry (ITC)
ITC experiments were conducted using an iTC200
instrument (MicroCal, GE Healthcare, Piscataway, NJ,
USA) at 25°C, set to deliver 40 injections (5 μl) at 180 s
intervals. In the titration experiments, 300 μM sodium
polytungstate in formulation buffer was injected from the
syringe to 30 μM epoetin, or to buffer in the measurement
cell. Changes in the temperature of the solution (ΔμCal)
were buffer- and dilution-corrected and integrated. The
integrated data were fit with a one-site binding model using
the Origin-7™ software provided from the manufacturer.
RESULTS
Analysis of the Study Medication for Risk Factors
for Immunogenicity
In response to the occurrence of two cases of neutralizing
antibodies during the pre-marketing clinical study with
subcutaneous use of epoetin alfa, a comprehensive clinical
and analytical investigation was implemented to determine
the root cause of neutralizing antibodies. The analytical
investigations included an in-depth risk assessment of the
following quality attributes that may be linked to immuno-
genicity based on previous reports in the literature (4–6, 8,
10): dimers/aggregates/particles; protein denaturation;
protein modification/degradation; leachates from the pri-
mary packaging; silicone oil; polysorbate micelles; host-cell
proteins and other process-related impurities (Table I). In-
depth analyses of retained and retrieved samples of those
batches that were used for treatment of the two patients
were performed and then compared with other batches
from the clinical trial and reference batches; these compar-
isons revealed no differences for almost all parameters with
the notable exception of aggregates, unfolded variants and
inorganic (tungsten) variants (Table I). As aggregation is
known to be highly relevant in the context of immunoge-
nicity of biopharmaceuticals (11), the study medication was
1456 Seidl et al.screened for this parameter with a wide range of orthogonal
analytical methods, including high-performance size exclu-
sion chromatography (HP-SEC), analytical ultracentrifuga-
tion (AUC), asymmetric-flow field-flow fractionation (AF4),
micro-flow imaging (MFI) and light obscuration (LO). The
selected methods make use of different separation and
detection principles to cover the complete size range of
soluble and insoluble aggregates as well as particles (28).
For most of the applied aggregation methods (with the
exception of HP-SEC, see below), no relevant differences
were observed between different batches of study medica-
tion and between study medication and reference batches.
Furthermore, the shape and morphology of detected
particles allowed the conclusion that detected particles were
silicone oil droplets derived from the surface of siliconized
syringes. In addition, a placebo batch showed similar levels
of particles allowing the conclusion that the observed
particles are non-proteinaceous. However, when drug
product batches (pre-filled syringes) of the study medication
were re-analyzed by routine HP-SEC for the presence of
dimers and higher-order aggregates, a small number of
individual syringes of two drug product batches (#260108
and #270108) were found to contain unusually high levels
of aggregation after the trial was terminated (Table II and
Fig. 1a). This observation was made when retained samples
and retrieved samples from the supply chain and the
different clinical centers were compared with reference
batches. Each patient in the study received the drug at only
Table I Overview of Most Relevant Risk Factors for Immunogenicity Investigated and Evaluation of Results
Potential risk factor Suspect batches had higher levels than? Literature available to suggest
a role in immunogenicity
Involvement in
current root-cause
Other batches
of study drug
Other batches not
used as study drug
Reference
product (Eprex
®)
Drug substance
Aggregation
a,b No No N/A Yes (10–12) Highly unlikely
Subvisible particles
a No No N/A Yes (13, 14) Highly unlikely
Oxidation Met-54
c No No N/A No Highly unlikely
Deamidation/aspartate
isomerization
a
No No N/A Yes (17) Highly unlikely
Unfolded variants
a No No N/A Yes (18) Highly unlikely
Host-cell proteins No No N/A Yes (19) Highly unlikely
Drug product
Aggregation
a,b Yes Yes No Yes (10–12) Most likely
Unfolded variants
a/irreversible
dimers
Yes Yes Yes Yes (18) Most likely
Subvisible particles
a No No No Yes (13, 14) Unlikely
Inorganic leachates
d Yes (tungsten) Yes (tungsten) Yes (tungsten) No
d Most likely
Organic leachates
b No No No Yes (8) Highly unlikely
Oxidation Met-54
c No No No No Highly unlikely
Oxidation Trp-64
c No No No No Highly unlikely
Deamidation/aspartate
isomerization
a
No No No Yes (17) Highly unlikely
Degradation
e No No No Yes (23, 24) Highly unlikely
Silicone oil
f No No No Unclear (5, 25–27) Highly unlikely
Polysorbate 80 micelles
g No No No No (5, 8, 28) Highly unlikely
aGenerally known to be a risk factor for immunogenicity of proteins
bSpecific reports/experience available in the context of immunogenicity of epoetins
cFor other products, e.g. interferon alpha 2b, it has been shown that metal-induced oxidation can increase immunogenicity. However, the oxidation was
not the direct immunogen but induced aggregation, which in turn increased immunogenicity (15, 16)
dThere are no reports that inorganic leachates may increase immunogenicity. However, data in the literature indicate that tungsten may induce aggregation
(20–22), which in turn can result in immunogenicity
eDisintegration of the primary structure as controlled by peptide mapping and capillary zone electrophoresis. Degradation could be fragmentation of the
protein backbone as well as modification of amino acids
fSilicone oil/gels may have adjuvant properties in animals but are not immunogenic per se. No case studies with biopharmaceutical products have been
published. However, silicone oil may induce aggregation, which in turn can increase immunogenicity (5, 25–27)
gIncorporation of epoetin into polysorbate 80 micelles was suggested as a risk factor (28), but was subsequently considered to be unlikely (5, 8)
Tungsten-Induced Aggregation of Epoetin 1457Table II Screening of the Study Medication for the Presence of Dimers/Aggregates: Results of QC SEC-HPLC Method (Results Printed in Blue Indicate
Batches which were Applied for Treatment of at Least One of the Patients with Neutralizing Antibodies; Results Printed in Red were Obtained with Study
Medication Retrieved from the Clinical Centres of One of the Two Affected Patients)
1458 Seidl et al.a single clinical center, the affected two patients either at
Clinical Center 6 or Clinical Center 336. However, study
medication was retrieved wherever possible from all clinical
centers and from the entire supply chain in order to
investigate if transport, storage or handling in the different
centers had an influence on the quality of the product.
There were no hints that the product was shipped, stored or
handled inappropriately or that handling and storage
instructions were violated. Individual syringes of batch
#260108 contained aggregation levels ranging from below
the limit of detection up to 5.1%; syringes from batch
#270108 contained aggregation levels ranging from below
the limit of detection up to 1.5% (Table II). On average,
pre-filled syringe batch #260108 contained higher levels of
aggregation than batch #270108, although both batches
were filled from the same compounded solution con-
taining material from the same drug-substance batch,
and both were produced using the same batch of
syringes. The two pre-filled syringe drug product
batches differed only in their filling volumes (300 μl
and 400 μl). These observations indicated that the
primary packaging (syringes) may play a role in the
aggregation of the active ingredient of these two
batches. Also the observed syringe-to-syringe variability
of the obtained aggregation values of these two batches
substantiated the suspicion that the cause of aggregation
is related to the primary packaging and not to the
manufacturing process of drug substance or drug
product. Reference batches used in the Eprex
® arm of
the clinical trial were also screened by HP-SEC, and
LOD: 0.06% for 3,000–5,000 IU and 0.40% for 1,000 and 2,000 IU, LOQ: 0.3% for 3,000–5,000 IU and 1.8% for 1,000 and 2,000 IU
Blue–Batches applied as study medication to the affected patients having developed neutralizing antibodies
Red–Retrieved samples of the clinical centres of the affected patients
Black–Further epoetin alfa batches used in the clinical trial or reference batches
Sample type:
RSS: Retained Sample stored at clinical trial sponsor
RSM: Retained Sample stored at drug product manufacturing site
CSS: Clinical Sample stored at clinical trial sponsor (batch after blinding)
CSC: Clinical Sample from the supply chain
CCxx: Clinical Centre xx (retrieved sample from clinical centre xx)
Table II (continued)
Tungsten-Induced Aggregation of Epoetin 1459aggregates were found at levels comparable to or even
higher than those found in the two suspect batches
(Table III). The Eprex
® batches were applied for the
treatment of approximately 50% of the patient population
of the clinical trial, however not for the treatment of the
patients that developed neutralizing antibodies.
Characterisation of Dimers and Aggregates
In order to investigate the characteristics of the dimers/
aggregates observed in the two suspect pre-filled syringe
drug product batches of epoetin alfa, samples of these
batches were also analyzed by a C4-RP-HPLC method that
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Fig. 1 Detection of dimers and aggregates in drug product batches of the study medication by HP-SEC and characterization of properties by C4-RP-
HPLC. (a) HP-SEC of the working standard (pink, negative control for dimers/aggregates), one syringe of epoetin alfa batch 260108 (blue) and one syringe
of Eprex
® batch 8JSSZ01; (b) C4-RP-HPLC of a temperature-stressed sample (pink, positive control for dimers/aggregates), epoetin alfa drug product
batch 260108 (blue) and one syringe of Eprex
® batch 8JSSZ01; (c) Zoom of the area in which the more hydrophobic compound elutes with the retention
time of irreversible dimers.
1460 Seidl et al.allows the detection of folding variants with different
hydrophobicity and/or irreversible dimers.
Samples of the study medication were also compared with a
temperature-stressed sample that contained stable dimers
(Fig. 1b) .U s i n gt h i sm e t h o di tw a ss h o w nt h a ts a m p l e so f
the suspect epoetin alfa batches contained a compound that
eluted from the C4-RP-HPLC column with a retention time
similar to that of the dimer fraction of the stressed control
sample. Therefore, it was concluded that a small proportion
of the total dimers was stable (or irreversible) and could not be
dissociated under the denaturing conditions of the C4-RP-
HPLC (Fig. 1b). In contrast, no irreversible dimers or folding
variants were detected in samples of Eprex
® study medication
by C4-RP-HPLC, although dimers/aggregates could be
detected by HP-SEC (Fig. 1b, c).
Assessments of Leachates from the Primary
Packaging
Syringes from suspect batches of the pre-marketing study
medication with a lower filling volume contained higher
levels of aggregation. This observation, in addition to the
significant syringe-to-syringe variability in the levels of
aggregation in these specific batches, suggested a role for
the syringe material (primary packaging) in the aggregation
of HX575. Therefore, the study medication was analysed
for leachables migrated from the primary packaging into
the formulation buffer.
No unexpected organic leachates from the syringes were
detected in the study medication, including the two suspect
batches of epoetin alfa, using three different HPLC
methods. More specifically, those organic leachates de-
scribed in the literature as involved in the increased
incidence of PRCA with Eprex
® (4, 5) were not detected.
Study medication was also screened for inorganic leachates,
and metal ions were quantified using ICP-OES. Soluble
tungsten was detected in drug product syringes of epoetin
alfa batches #260108 and #270108 in which unusual high
levels of aggregates were found (Table IV, approximately
1 ppm on average; up to 4 ppm in individual syringes). This
led to a more extensive investigation of the impact of
tungsten on aggregation of the glycoprotein. For all other
Table III Results of the Determination of Dimers and Aggregates in the Study Medication of the Eprex
® Arm of the Clinical Trial
Batch Strength Aggregates at implementation
into clinical trial
Aggregates at expiry date
(18 months) or at the end of clinical trial
Age at the end of
clinical trial
7ASSS01 1,000 IU <LOD <LOD 18 months
7ESSW02 1,000 IU <LOD <LOD 18 months
7JSSJ00 1,000 IU <LOD <LOD 18 months
7KSSH00 1,000 IU <LOD <LOD 18 months
8ESSU00 1,000 IU <LOD <LOQ 14 months
7BSSG00 2,000 IU <LOQ <LOD 18 months
7EST000 2,000 IU <LOD <LOD 18 months
7GSSR00 2,000 IU <LOD <LOD 18 months
7JSS300 2,000 IU <LOD <LOD 18 months
8BSSE00 2,000 IU <LOD <LOQ 17 months
8DSSB00 2,000 IU <LOQ <LOD 15 months
7CSST00 3,000 IU <LOD 1.7% (n=4, variability from 1.3 to 1.9%) 18 months
7FSSY02 3,000 IU <LOD 2.9% (n=4 from 2.3 to 4.1%) 18 months
7GSSU02 3,000 IU <LOD 0.6% (n=4 variability from 0.3 to 1.4%) 18 months
8ASSR01 3,000 IU <LOD 1.3% (n=50, variability from 0.2% to 5.3%) 18 months
8DSSY00 3,000 IU 1.3% (n=6, variability from <LOD to 3.2%) 1.1% 15 months
7CSSY00 4,000 IU <LOD <LOD 18 months
7EST401 4,000 IU <LOD 1.2% 18 months
8BSSG01 4,000 IU <LOD 1.7% 17 months
8ESSK02 4,000 IU <LOD 1.0% 14 months
7BSSQ00 5,000 IU <LOD <LOD 18 months
7EST802 5,000 IU <LOD <LOD 18 months
7KSSU00 5,000 IU <LOD 1.2% 18 months
8GST300 5,000 IU 0.9% 0.6% 12 months
LOD: 0.06% for 3,000–5,000 IU and 0.40% for 1,000 and 2,000 IU, LOQ: 0.3% for 3,000–5,000 IU and 1.8% for 1,000 and 2,000 IU
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1462 Seidl et al.metal ions analyzed no differences were observed between
the different batches of the study medication and the
reference batches.
Influence of Tungsten on Aggregation of Epoetin Alfa
Tungsten Spiking Studies
A series of studies were performed in which epoetin alfa drug
product solution (336 μg/ml) was spiked with a range of
tungsten species at concentrations of approximately 2 and
20 ppm. The spiked samples were incubated with tungsten (IV)
oxide, tungsten (VI) oxide; sodium tungstate dihydrate, sodium
polytungstate, ammonium tungstate or tungsten metal powder
at 5°C and 25°C for up to 9 months and then analyzed for the
presence of dimers and higher-order aggregates. Samples
spiked with 20 ppm sodium polytungstate were prone to
aggregation as dimers and higher molecular weight forms were
detected by HP-SEC (Fig. 2a) and their content increased
during storage at 5°C and 25°C. Analysis by C4-RP-HPLC
confirmed the presence of a compound with higher hydro-
phobicity, similar to the compound found in the samples of
the epoetin alfa study medication (Fig. 2b).
Tungsten-spiked samples were also analyzed by SDS-
PAGE/silver staining under reducing and non-reducing
conditions. Under non-reducing conditions (Fig. 2c), three
bands were visible after silver staining that were interpreted
as monomer, dimer and higher-molecular-weight aggre-
gates. Under reducing conditions (Fig. 2d), only the
monomer was visible after silver staining, indicating that
the dimer and higher aggregates were linked by disulphide
bonds.
Tungsten Pin Extract Studies
Spiking studies were also performed using tungsten species
originating from tungsten pins used to manufacture the
syringes in which the final product was provided for use.
Epoetin alfa drug product solution (336 μg/ml) was spiked
withpinextracttotungstenconcentrationsofapproximately2
and 20 ppm. The spiked samples were incubated at 5°C and
25°C for up to 6 months and then analyzed by HP-SEC for
the presence of dimers and higher-order aggregates. No
aggregation was detected in any spiked sample less than
6 months old, irrespective of the tungsten level or
incubation temperature (Table V). However, small
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Fig. 2 Characterization of polytungstate-induced aggregation (20 ppm sodium polytungstate incubated for 3 months at 25°C) of epoetin alfa drug product
with orthogonal analytical methods. (a) Detection of dimers and higher aggregates by HP-SEC; (b) Detection of the irreversible dimer fraction by C4-RP-
HPLC; (c) Detection of dimers and higher aggregates by SDS-PAGE under non-reducing conditions; (d) SDS-PAGE of the sample incubated with
polytungstate under reducing conditions (dissociation of aggregates with 2-mercaptoethanol). SDS-PAGE: Bands which are assigned to dimers and
aggregates are marked with red arrows. Lane 1 = molecular weight marker: lane 2 = epoetin alfa reference sample without polytungstate (negative
control): lane 3 = epoetin alfa drug product (336 μg/ml) spiked with 20 ppm sodium polytungstate.
Tungsten-Induced Aggregation of Epoetin 1463amounts of aggregates were detected in spiked samples
stored for at least 6 months; the level of aggregation was
highest in samples spiked to 20 ppm tungsten and
incubated at 25°C.
Tungsten Binding and Tungsten-Induced Unfolding
of Epoetin Alfa
The tungsten spiking experiments showed that sodium
polytungstate has a strong potential to induce epoetin alfa
aggregation. In order to assess the impact of the various
tungsten species on the higher order structure of epoetin
alfa, CD analysis of epoetin alfa–tungsten coincubated
samples was performed. Samples were assayed either
directly (in presence of the tungsten compound) or
indirectly (after removal of insoluble tungsten via centrifu-
gation). The various tungsten forms tested either caused
partial depletion of epoetin alfa from solution (via adsorp-
tion), or altered the structural conformation of the epoetin
alfa remaining in solution (data not shown). Again, sodium
polytungstate had the strongest effect among the six
tungsten compounds investigated, inducing significant
structural changes in epoetin alfa. Therefore, the binding
behaviour and influence of sodium polytungstate on the
secondary structure of epoetin alfa was further assessed
using SPR spectroscopy, ITC and CD spectroscopy. SPR
spectroscopy demonstrated that sodium polytungstate binds
rapidly to epoetin alfa and also dissociates rapidly, with an
apparent KD of 10.2±2.7 μM (Fig. 3). The KD determined
by ITC (10.3 μM) was consistent with the SPR value, and
ITC results indicated a 1:1 binding stoichiometry between
sodium polytungstate and epoetin alfa (data not shown).
The unfolding kinetics of 84 μg/ml (2.76 μM) epoetin alfa
spiked with 20 ppm (6.7 μM) sodium polytungstate at 20°C
were monitored in real time, with a series of far-UV CD scans
at intervals of approximately 2 min (Fig. 4). An effect of
sodium polytungstate was detectable as little as 2 min after
spiking of epoetin alfa, as indicated by the immediate onset of
changes both in quantity (amplitude) and quality (signature)
of the observed far-UV CD signal (Fig. 4a). Our observations
indicate that the majority of the structural damage to epoetin
alfa occurred approximately within the first 30 min of its
interaction with sodium polytungstate (Fig. 4b). The observed
unfolding of the protein during short-term incubation with
polytungstate was largely reversible upon removal of the
tungsten by dialysis. Furthermore, a direct effect of tungsten
Table V Aggregate Content of Epoetin Alfa Samples Spiked with Tungsten Pin Extract (0, 2 or 20 ppm) and Stored for 6 Months at 5°C or 25°C
(Determination by HP-SEC)
Tungsten
concentration (ppm)
Storage
temperature (°C)
Epoetin alfa
monomer (relative area, %)
Epoetin alfa
dimer (relative area, %)
Epoetin alfa higher
aggregates (relative area, %)
0 5 100.00 ND ND
2 5 99.95 0.05 ND
20 5 99.33 0.42 0.25
0 25 99.48 0.52 ND
2 25 99.41 0.59 ND
20 25 97.67 1.72 0.61
c [µM]
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Fig. 3 SPR analysis of the interaction between immobilized epoetin alfa
and sodium polytungstate. (a) Sodium polytungstate was injected at 25°C
for 10 min at a flow rate of 10 μL/min (concentrations as indicated in
figure inlay); (b) Plot of steady-state binding values (RU) versus sodium
polytungstate concentration (μM).
1464 Seidl et al.from a tungsten pin extract was detected in real-time CD
experiments (data not shown).
DISCUSSION
A battery of methods was applied to assess the quality
attributes of drug-substance and drug product syringes in
order to identify the potential root cause(s) of the two cases
of neutralizing antibodies to erythropoietin in an investiga-
tional study. Retained and retrieved samples of batches
applied to the two affected patients were compared with
reference batches, other study drug batches and Eprex
®.
Unexpected results were obtained when the study
medication was intensively evaluated for the presence of
dimers and higher aggregates. Aggregation is recognised as
an important factor in the breakdown of immune tolerance
resulting in immunogenicity of therapeutic proteins (6, 8,
11, 30). Therefore, special emphasis was placed on this
parameter. In addition to the HP-SEC method used
routinely for quality control purposes, numerous orthogo-
nal methods were employed; the methods used are based
on different separation and detection principles to cover the
complete size range of soluble and insoluble aggregates as
well as subvisible and visible particles (13, 14, 29). For
almost all methods applied, no relevant differences were
detected in the batches used as study medication for the two
affected patients, as compared with all other samples (other
batches of the study medication and reference samples).
Unexpectedly, an increased level of dimerisation/aggrega-
tion (in the aggregate size range covered by the routine
quality control HP-SEC method) was detected in two drug
product batches that were used to treat the affected
patients. The level of dimers/aggregates detected in these
suspect batches (up to 5% in individual syringes) had never
previously been found for the drug product (pre-filled
syringes), neither at release of any drug product batch nor
in stability studies of batches until the end of their shelf-life.
Despite the fact that almost 50% of tested Eprex
®
batches used in the clinical trial contained levels of dimers
and aggregates comparable to or higher than those in the
two suspect batches of HX575, no patients treated with
Eprex
® in the clinical study developed neutralizing anti-
bodies. It is possible that this is purely a matter of chance,
although an alternative explanation might be that specific
characteristics of aggregates rather than the absolute level
are important for the breakdown of immune tolerance. We
therefore sought to characterize the nature of the protein
dimers/aggregates in the suspect batches of the study
medication, using newly established analytical techniques.
These techniques indicated that the aggregated samples
contained a species with higher hydrophobicity, which
could be related to different folding or to a dimer fraction
that could not be dissociated in the presence of organic
solvents. Further tests showed that a proportion of these
irreversible dimers could be dissociated only in the presence
of reducing agents, indicating that they are covalently
linked by disulphide bonds. These hydrophobic species
could not be detected in samples of the Eprex
® medication
used in this study.
The two suspect batches of epoetin alfa differed only in
their filling volumes, and the batch with the lower filling
volume contained a higher level of aggregates. This finding,
along with the observed variability in the level of aggregates
from syringe to syringe, indicated the involvement of
additional factors related to the syringes used as primary
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Fig. 4 Time-resolved epoetin alfa CD unfolding kinetics after addition of
sodium polytungstate. (a) Overlay of far UV CD scans of epoetin alfa
(84 μg/mL) before (cyan), shortly after (2–18 min, other colors), 30 min
after (dark red) and 20 h after (dashed line) spiking with 20 ppm sodium
polytungstate. Scans were collected every 2 min, starting from 2 min after
the spiking event, until 18 min after spiking. Arrows indicate the start and
endpoint scans. Inlays show enlarged views of 1) the region where the
CD signal of epoetin alfa shifts from positive to negative (λ0) and 2) the
region of the negative CD signal maximum around 208 nm; (b) Relative
loss of CD signal at 208 nm after spiking with 20 ppm sodium
polytungstate, monitored over 30 h.
Tungsten-Induced Aggregation of Epoetin 1465packaging. Several recent reports have implicated tungsten
as a causative factor in the aggregation of pharmaceutical
protein products (20–22). The tungsten most likely origi-
nates from tungsten pins used to form the barrels of the
glass syringes in which the final product is provided for use
(22). Our investigations detected tungsten in drug product
extracts of the two suspect epoetin alfa clinical batches. We
subsequently showed that sodium polytungstate, as well as
an extract of the tungsten pins used to manufacture the
syringes, induced dimerization/aggregation of epoetin alfa
clinical product. These aggregates were similar to those
detected in the two suspect batches of the study medication
from the clinical trial, in that a proportion of the dimers
could not be dissociated by organic solvents and were most
likely covalently linked via disulphide bonds. We also
demonstrated that sodium polytungstate can bind rapidly
and reversibly to epoetin alfa and has a strong denaturing
effect on the secondary structure of epoetin alfa clinical
product, inducing rapid unfolding of the glycoprotein.
In addition to the aggregated species detected in the
study medication, it is also possible that unfolded protein
molecules might directly induce an immune response, by
revealing novel epitopes that induce the formation of
antibodies capable of cross-reacting with endogenous
erythropoietin. This is more likely to occur after subcuta-
neous administration than after intravenous administration.
Dilution of unfolded/aggregated protein and tungsten is
likely to occur much less rapidly after subcutaneous
administration due to restrictions in space, and therefore
diffusion and movement of the administered solution,
imposed by the subcutaneous extracellular matrix and cells.
By contrast, dilution of unfolded/aggregated protein and
any tungsten present (and therefore renaturation of the
protein) will likely occur very rapidly after intravenous
administration due to the large volume of blood and
associated admixture.
The aggregation found in the suspect batches of the
study medication is clearly linked to the drug product
manufacturing process of producing pre-filled syringes,
since dimers and aggregates were not detected in drug-
substance samples. In contrast to this, literature reports
have indicated the presence of dimers/aggregates not only
in Eprex
® drug product but also in the drug substance at
levels of approximately 1% (31,32), suggesting dimers/
aggregates in Eprex
® may be derived also from other steps
in the overall manufacturing process than just the drug
product manufacturing. The potential differences in origin
and cause of unfolding and/or aggregation may explain the
different structural characteristics of the dimers/aggregates
detected in the study medication and the used Eprex
®
batches, and consequently the different immunogenic
potential in this clinical trial. On the other hand, PRCA
continues to occur at a very low incidence with the clinical
use of Eprex
® and other epoetins (3,33–35), despite the
introduction of coated rubber stoppers which should have
removed the previously hypothesized root cause of the
PRCA outbreak associated with Eprex
® between 1998 and
2002 (4,5). Therefore, further investigation may be war-
ranted of the role of unfolding and formation of irreversible
dimers/aggregates as a root cause in the development of
neutralising antibodies with epoetins. This suggestion is
further supported by a recent report implicating aggregation
as the root cause of PRCA cases following inappropriate
transport and storage of Eprex
® (12).
Considering recent reports on process changes imple-
mented by a manufacturer of ready-to-fill syringes leading
to higher residual tungsten levels in the syringes (22), and
together with previous reports of tungsten-induced aggre-
gation of pharmaceutical proteins (20–22), our findings
highlight the importance of improving the manufacturing
process for syringes to reduce the tungsten content to
consistently low levels. The manufacturer of these clinical
supplies has converted all syringes to low-tungsten compo-
nents to prevent further excursions of tungsten and
formation of these identified aggregates in future.
The results of the investigations could explain the root
cause of the occurrence of two cases of neutralizing
antibodies in an investigational clinical trial, and adds
tungsten-induced unfolding to the list of previously de-
scribed root causes for PRCA, among which are leachates
from the primary packaging acting as adjuvants and heat-
induced aggregation (4,5,12). Our finding may also be
more broadly applicable to this and other classes of
therapeutic proteins and may contribute to a better
understanding of immunogenicity of biopharmaceuticals.
CONCLUSIONS
We propose tungsten-mediated unfolding and aggregation of
epoetin alfa in pre-filled syringes as a potential root cause for
increased immunogenicity.Thisfinding may bemorebroadly
applicable to this and other classes of therapeutic proteins.
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